ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

Abstract Inflammatory myofibroblastic tumors are rare mesenchymal neoplasms frequently harboring oncogenic chromosomal rearrangements, most commonly, involving the ALK (anaplastic lymphoma kinase) gene. Treatment of this molecularly defined subgroup with the anaplastic lymphoma kinase inhibitor criz...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sebastian Y. F. Michels, Andreas H. Scheel, Thomas Wündisch, Johannes M. Heuckmann, Roopika Menon, Michael Puesken, Carsten Kobe, Helen Pasternack, Carina Heydt, Matthias Scheffler, Rieke Fischer, Anne M. Schultheis, Sabine Merkelbach-Bruse, Lukas Heukamp, Reinhard Büttner, Jürgen Wolf
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/33a80232e38044a3a05d9a9bbd74b52a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/33a80232e38044a3a05d9a9bbd74b52a

Ejemplares similares